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Abstract
Type 2 diabetes is a metabolic disorder characterized by the inability of beta-cells to secrete enough insulin to maintain
glucose homeostasis. MIN6 cells secrete insulin in response to glucose and other secretagogues, but high passage (HP)
MIN6 cells lose their ability to secrete insulin in response to glucose. We hypothesized that metabolism of glucose and lipids
were defective in HP MIN6 cells causing impaired glucose stimulated insulin secretion (GSIS). HP MIN6 cells had no first
phase and impaired second phase GSIS indicative of global functional impairment. This was coupled with a markedly
reduced ATP content at basal and glucose stimulated states. Glucose uptake and oxidation were higher at basal glucose but
ATP content failed to increase with glucose. HP MIN6 cells had decreased basal lipid oxidation. This was accompanied by
reduced expressions of Glut1, Gck, Pfk, Srebp1c, Ucp2, Sirt3, Nampt. MIN6 cells represent an important model of beta cells
which, as passage numbers increased lost first phase but retained partial second phase GSIS, similar to patients early in type
2 diabetes onset. We believe a number of gene expression changes occurred to produce this defect, with emphasis on Sirt3
and Nampt, two genes that have been implicated in maintenance of glucose homeostasis.
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Introduction
Type 2 diabetes (T2D) is characterized by the inability of beta-
cells to secrete enough insulin to maintain glucose homeostasis,
usually accompanied by insulin resistance: impaired action of
insulin on target tissues. Beta-cells secrete insulin in a biphasic
manner. The first phase occurs rapidly, commonly defined as ,10
minutes after glucose stimulation. In the whole body, insulin
secretion normally peaks at 1–2 minutes [1]. Second phase
secretion is more gradual and long lasting, typically reaching a
plateau at 25–30 minutes [1].
The classic pathway of insulin secretion is generally accepted
and begins with glucose entry into beta-cells, and a rise in the
ATP:ADP ratio as glucose is metabolized via glycolysis and
oxidative phosphorylation [2–4]. This closes ATP-dependent K+
channels (KATP) and depolarizes the plasma membrane [5,6]. This
then opens the voltage-gated calcium channels, allowing Ca2+ to
enter the cells, leading to subsequent insulin exocytosis [7].
Interestingly, patients early in the course of T2D lose first phase
but often retain second phase insulin secretion [8]. Impairment of
first phase secretion is a predictor of future type 1 and T2D risk
[9]. Many additional mechanisms regulate insulin secretion
including the rate of anapleurosis and changes in glutamate,
GTP, and GDP levels (all of which are involved in the amplifying
pathway) [4].
The MIN6 cell line was derived from a mouse insulinoma and is
one of a few cell lines that display characteristics of pancreatic
beta-cells, including insulin secretion in response to glucose and
other secretagogues [10,11]. It has been reported that MIN6 cells
with high passage (HP) numbers lose their ability to secrete insulin
[12–14]. HP MIN6 cells have gene expression changes, including
downregulation of genes such as phospholipase D1 and cholecystokinin
[14].
HP and low passage (LP) MIN6 cells also differ at the protein
level, with HP cells having lowered expression of some proteins
that are involved with correct protein folding in the ER and
antioxidant enzymes for handling of ROS [12]. This is in contrast
to studies comparing glucose responsive and unresponsive sublines
of LP MIN6 cells, with one study showing no change in Glut2
expression [15] while another study showing barely detectable
Glut2 expression, even in their glucose responsive MIN6 cell line
[16].
These studies showed changes in gene and protein expression,
however metabolic changes have not been profiled with a panel of
functional assays in detail before. We sought to identify changes
associated with impaired insulin secretion in HP cells. HP cells lost
first phase insulin secretion and had an overall impairment in
GSIS. This was coupled with a markedly reduced intracellular
ATP in HP cells, with decreased glucose uptake, glucose oxidation
and basal lipid oxidation. HP MIN6 cells had significantly reduced
expression of glycolytic genes and genes involved with lipid
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handling, including Srebp1c. This was accompanied by a decrease
in Sirt3 and Nampt gene expression.
Materials and Methods
Cell Culture
We obtained MIN6 cells from Dr. Ross Laybutt (Garvan
Institute of Medical Research) [17] (originally from Dr Miyazaki
[11]) and cells were routinely maintained in Dulbecco’s modified
Eagle’s medium (DMEM) containing 25 mM glucose, supple-
mented with 10% fetal calf serum, 2 mM L-glutamine, 25 mM
Hepes, and 285 mM 2-mercaptoethanol. Subculture and mainte-
nance were performed as previously described [13]. MIN6 cells
presented in this study were at passages 30–40 (low passage, LP) or
passages 60–70 (high passage, HP). We compared earlier passage
cells (P26–27) and they did not differ in normal GSIS from P30–40
(data not shown). All assays used MIN6 grown to 70–80%
confluence unless otherwise stated.
Electron Microscopy
Electron microscopy samples were fixed for 30 minutes in
cacodylate buffered 2% glutaraldehyde. Samples were post-fixed
for 90 minutes in 2% osmium tetroxide and then enbloc stained
with 2% aqueous uranyl acetate (30 minutes). Samples were
dehydrated through a series of ethanols and infiltrated with TAAB
epoxy resin. The blocks were set at 80uC overnight. Methylene
blue/Azure II stained thick sections were used to identify suitable
areas of the blocks which were cut at 100 nm. These sections were
collected on Cu/Pd grids, stained with Reynolds lead citrate and
viewed on a JEOL 1011 electron microscope with images captured
using a MegaView III digital camera and AnalySIS software
package.
Cell Proliferation
Cell proliferation was examined using the FITC BrdU Flow Kit
(BD Pharmingen, San Diego, CA, USA). MIN6 cells were pulsed
with 10 ml/ml of BrdU solution (1 mM BrdU in PBS) for 40
minutes in MIN6 media at 37uC with 5% CO2. Cells were
dislodged by trypsin. BrdU and 7AAD staining was performed as
per the protocol. Flow cytometric data was acquired using a FACS
Calibur (BD Biosciences, San Jose, CA, USA) and FlowJo software
(Tree Star).
Insulin Secretion Assays
Media used for insulin secretion was serum free DMEM with no
glucose, supplemented with 2 mM L-glutamine and 25 mM
Hepes, pH 7.4. Glucose was added to prepare basal (1 mM) and
other glucose concentrations (3.3 mM, 5.5 mM, 11 mM, and
25 mM) and warmed to 37uC prior to use. MIN6 cells were
washed twice with PBS and placed in basal serum free media for 2
hours, washed with fresh basal media and placed in the stated
media for 15 minutes. Media was then replaced with media
containing higher concentrations of glucose for 15 minutes. 15
minutes was the minimum time necessary for the cells and culture
media to reach 37uC (approx. 5 minutes) and insulin secretion
(approx. 10 minutes) to occur. After completion of the incubations,
the cells were lysed with acid/ethanol for measurement of total
insulin content as previously reported [18,19]. Insulin secretion
with addition of 1 mM pyruvate, 30 mM L-arginine, or 30 mM
KCl was performed after an incubation time of 30 minutes.
Bromopalmitate (0.0625 mM) was added 2 hours before insulin
secretion assays.
For insulin secretion time courses, MIN6 cells were grown in
12-well plates and samples for basal 1 mM insulin secretion was
collected as above. After the addition of 25 mM serum free media,
10 ml was removed at each time point (2, 5, 10, 15, 30, 60 minutes)
and total insulin collected as described above. Insulin was
measured by ELISA (Crystal Chem, Downers Grove, IL, USA).
Measurement of Intracellular ATP Content
Intracellular ATP content was measured using the ATP
Bioluminescence Assay Kit CLS II (Roche, Sydney, NSW,
Australia) according to the manufacturer’s instructions. Cells were
equilibrated as described above then serum free media was
replaced with fresh basal media. Glucose was added to make up to
25 mM at each time point. MIN6 cells were placed on ice, washed
twice with ice cold PBS, and lysed. Results were corrected for total
protein.
Glucose Oxidation Assay
MIN6 cells were grown in 25 cm2 flasks, washed twice with
PBS, and incubated in Krebs buffer (115 mM NaCl, 4.7 mM
KCl, 1 mMMgSO4, 1.2 mMKH2PO4, 25 mM NaHCO3, 1 mM
sodium pyruvate, 10 mM Hepes, pH 7.4) with 1mM glucose for 2
hours. After equilibration, cells were washed with fresh Krebs
buffer with 1mM glucose and media replaced with fresh Krebs
buffer at 1, 5, 11, or 25 mM glucose with 0.1 mCi/ml of D-
[U-14C]-glucose (GE Healthcare, Port Washington, NY, USA).
Filter paper soaked in 5% KOH was suspended over the cells and
the flasks sealed shut. Cells were incubated at 37uC with 5% CO2
for 1 hour and the reaction stopped by the addition of perchloric
acid. Radioactivity was counted in 4 ml Microscint-20 (Perkin
Elmer, Waltham, Massachusetts, USA) using the LS 6500
Scintillation Counter (Beckman Coulter, Brea, CA, USA). Results
were corrected for specific activity and total protein.
Glucose Uptake Assay
MIN6 cells were grown in 6-well plates and equilibrated as per
glucose oxidation protocols. After washing, media was replaced
with fresh warm Krebs buffer with 1 or 25 mM glucose and
1 mCi/ml 2-deoxy-[1,2-3H]-glucose (Perkin Elmer, Waltham,
Massachusetts, USA). Cells were incubated at 37uC with 5%
CO2 for exactly 5 minutes. The reaction was stopped by placing
on ice and washing twice with ice cold 5% glucose in PBS. Cells
were lysed with 500 ml of RIPA buffer (0.5% sodium deoxycho-
late, 50 mM Hepes, 1% NP40, 0.1% SDS, pH 7.4) and counted
as above. Results were corrected for total protein.
Figure 1. Insulin secretion in LP and HP MIN6 cells. A) LP MIN6 cells responded in a dose dependent manner to glucose but this was not
observed in HP MIN6 cells (samples taken at 15 minutes after stimulation, representing first phase insulin secretion). B) A GSIS time course showed
that HP MIN6 cells still retained partial second phase insulin secretion, although significantly lower than that observed in LP MIN6 cells. C) After an
incubation time of 30 minutes, LP MIN6 cells responded well to the non glucose secretagogues L-arginine and KCl. HP MIN6 cells showed no
augmentation in insulin secretion with L-arginine but responded to KCl, with levels comparable to LP MIN6 cells. Error bars are 6 SEM and n= 6.
* p,0.05 compared to LP MIN6 cells at basal,# p,0.05 compared to HP MIN6 cells at basal, @ p,0.05 LP vs. HP MIN6 cells at their respective glucose
concentrations or time points.
doi:10.1371/journal.pone.0040868.g001
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Figure 2. Intracellular ATP content in LP and HP MIN6 cells. A) Time course showing the fold change in intracellular ATP content. HP MIN6
cells only exhibited significant fold change differences from basal ATP content at 2 and 15 minutes after glucose stimulation. LP MIN6 cells had
significantly higher fold changes from basal after 10 minutes of glucose stimulation. B) Time course showing the intracellular ATP molar
concentration. HP MIN6 cells had significantly less intracellular ATP content at all time points. Error bars are 6 SEM and n=6. * p,0.05 compared to
LP MIN6 cells at basal, # p,0.05 compared to HP MIN6 cells at basal, @ p,0.05 LP vs. HP MIN6 cells at their respective time points.
doi:10.1371/journal.pone.0040868.g002
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Figure 3. Morphology and cell proliferation in LP and HPMIN6 cells. A) Pointed formations (as indicated by the arrows) were observed in HP
MIN6 cells and appeared more irregular than LP MIN6 cells. B) Electron microscope pictures of LP and HP MIN6 cells under low magnification. HP
MIN6 cells were larger compared to LP MIN6 cells (200.56 mM2 versus 111.89 mM2, p,0.05). C) LP MIN6 cells displayed distribution and frequency of
insulin granules (as indicated by the arrows) typical of an islet cell while HP MIN6 cells had slightly less insulin granules. D) Representative FACS plot
of BrdU and 7AAD staining. HP MIN6 cells had a lower percentage of cells in the S phase of DNA replication (5.4% versus 11.9%, p,0.05). Errors values
are 6 SEM and n= 3.
doi:10.1371/journal.pone.0040868.g003
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Lipid Oxidation
MIN6 cells were grown in 25 cm2 flasks, washed twice with
PBS, and incubated in Krebs buffer plus 0.25% fatty acid free BSA
(Sigma-Aldrich, St. Louis, MO, USA) with 1 mM glucose at 37uC
with 5% CO2 for 2 hours. After equilibration, cells were washed
with fresh Krebs+BSA buffer with 1 mM glucose and media
replaced with fresh Krebs+BSA buffer at 1 or 25 mM glucose
concentrations with 0.125 mM palmitate and 0.25 mCi/ml of
[1-14C]-palmitic acid (GE Healthcare, Port Washington, NY,
USA). Filter paper soaked in 5% KOH was suspended over the
cells and the flasks sealed shut. MIN6 cells were incubated at 37uC
with 5% CO2 for 24 hours and the reaction stopped by the
addition of perchloric acid. Radioactivity was measured as above.
Results were corrected for total protein.
Measurement of Lactate
Cells were incubated in serum free media containing 1 or
25 mM glucose for 2 hours and lactate was measured using the
BioVision Lactate Assay Kit II (BioVision, Mountain View, Cal,
USA) according to manufacturer’s protocol. Results were correct-
ed for total protein.
Real-time PCR
RNA was isolated as previously described [18] and real-time
PCR performed as previously described [18,19]. Primer sequences
are available on request. Every plate included a house-keeping
gene (TATA-box binding protein (TBP)) for LP and HP cells.
Statistical Analysis
For all figures, error bars indicate 6 SEM. Unpaired 2-tailed t-
tests were used to compare two variables, and ANOVA with post-
hoc testing (Bonferoni or Tukey’s) was used for multiple
comparisons. A p-value of ,0.05 was considered significant.
Results
Insulin Secretion
Low passage (LP) was defined as passages 30–40 and high
passage (HP) as passages 60–70. As shown in Figure 1A, LP cells
displayed a dose response in insulin secretion when stimulated with
increasing glucose concentrations. This culminated in a ,1.7-fold
increase in insulin secretion with high glucose (25 mM) (p,0.05).
This response was not observed in HP cells. There was a trend for
higher insulin release at basal glucose (1 mM, p=0.2, data not
shown). Glucose stimulated insulin secretion time courses were
studied and as expected, LP MIN6 cells secreted increasing
amounts of insulin over time (Figure 1B). Interestingly, HP cells
eventually responded to glucose at 60 minutes, however this was
still significantly less than LP MIN6 cells (p,0.05). Thus, HP cells
had an overall impairment in GSIS, with a more severe effect on
first phase secretion.
Non-glucose secretagogues were next used. Potassium chloride
(KCl) treatment at 30 mM induced strong and equivalent insulin
secretion in both LP and HP cells, demonstrating that HP cells
were still able to secrete insulin. KCl stimulated insulin secretion in
HP was significantly greater than with 25 mM glucose (p,0.05,
Figure 1C). L-arginine, is a potentiator of GSIS, was effective in
both cells (p,0.05, Figure 1C) but HP cells did not achieve levels
near those in LP cells or with KCl stimulation.
Intracellular ATP Content in Low and High Passage MIN6
Cells
LP cells responded to 25 mM glucose with increased ATP
content, resulting in significant increases over basal levels from 10
minutes onwards (p,0.05, Figure 2A). This was not observed in
HP cells, with the only significant increase at 15 minutes
(Figure 2A). Figure 2A shows the intracellular ATP content
expressed as a fold change compared with their respective basal
levels. Surprisingly, there was a significant decrease in ATP
content at 5 minutes in HP cells, which was not seen in LP cells
(p,0.05). Figure 2B shows the ATP data expressed as raw
numbers. LP cells had at least 5-fold higher ATP at all time points
compared to HP cells (p,0.01).
Morphology and Cell Cycle Progression
Morphologically, LP MIN6 cells generally appeared round
whereas the HP cells had a more irregular shape with pointed
protrusions (Figure 3A). Cells were viewed under an electron
microscope. HP cells were larger with an average size of
200.56 mM2 compared to an average size of 111.89 mM2 in LP
MIN6 cells (p,0.05, Figure 3B). The distribution and frequency of
insulin granules in LP MIN6 cells were typical. However, there
were reduced insulin granules per field of view in HP cells
(Figure 3C, representative insulin granules are indicated with an
arrow).
To determine whether HP MIN6 cells might be consuming
ATP due to increased cell proliferation, flow cytometry analysis of
BrdU incorporation and 7AAD staining in was performed. HP
cells had a lower percentage of cells in S phase of DNA replication
(5.4% versus 11.9%, p,0.001, Figure 3D). This suggests that HP
cells were not utilizing ATP by more rapid cell cycling.
Glucose Oxidation, Glucose Uptake, and Lipid Oxidation
Glucose uptake was measured using the glucose analogue 2-
deoxy-[1,2-3H]-glucose. In cells where there is active glucose
uptake, such as differentiated C2C12 myotubes, there is ,50%
decrease in 2-deoxy-[1,2-3H]-glucose uptake from basal to high
glucose conditions, due to dilution by ‘cold’ non-radioactive
glucose [20]. Figure 4A shows an estimation of total glucose
uptake in the cells (i.e. including calculated uptake of non-
radioactive glucose uptake plus 2-deoxy-[1,2-3H]-glucose). Inter-
estingly, HP cells had approximately 3-fold higher 2-deoxy-
[1,2-3H]-glucose uptake at basal glucose versus LP cells (p,0.01)
but decreased uptake at 25 mM glucose suggesting that their
uptake was at a greater proportion of maximal capacity at baseline
Figure 4. Glucose uptake, glucose oxidation, and lipid oxidation in LP and HP MIN6 cells. A) Both LP and HP MIN6 cells had a significant
increase in total glucose uptake from 1 to 25 mM glucose when compared to 1 mM glucose uptake in LP cells. B) When fold change in glucose
uptake is compared to their respective basal levels, HP cells only had an approximate 7-fold increase compared to an approximate 38-fold increase in
LP cells. C) LP MIN6 cells exhibited a dose response in glucose oxidation when stimulated with increasing amounts of glucose. HP MIN6 cells did not
show this response, with an 8-fold increase in glucose oxidation at 1 mM glucose and only increasing by 1.8-fold at 25 mM glucose. D) Glucose
oxidation in low and high passage MIN6 cells expressed as the fold change compared to LP MIN6 cells at 1 mM glucose. E) HP MIN6 showed no
preferential lipid oxidation at low glucose concentrations as that seen in LP MIN6 cells. There were no significant differences in lipid oxidation
between 1 and 25 mM glucose in HP MIN6 cells. F) There was a significant increase in lactate from 1 to 25 mM glucose. G) 0.0625 mM bromopalmitate
treatment for 2 hours would seem to increase insulin secretion but total insulin values content was low indicating cell death. H) Raw insulin values
showing reduced insulin secretion with bromopalmitate treatment in both LP and HP MIN6 cells. Error bars are 6 SEM and n=6. * p,0.05.
doi:10.1371/journal.pone.0040868.g004
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(Figure 4A). Both low and HP cells had a significant increase in
calculated total glucose (radioactive plus non radioactive) uptake
from 1 to 25 mM glucose which was ,50% greater in LP cells,
although not significant (Figure 4A). However, Figure 4B shows
the fold-change in total glucose uptake compared to their
respective basal levels. LP cells had ,38-fold increase from 1 to
25 mM glucose whereas HP cells only had ,7-fold change
(p,0.05).
Glucose oxidation was measured by the amount of 14CO2
production from the breakdown of D-[U-14C]-glucose. LP cells
exhibited a dose dependent increase in glucose oxidation with
,28-fold increase from 1 to 25 mM glucose (p,0.001). Consistent
with their increased basal glucose uptake, HP cells had an 8-fold
higher basal glucose oxidation (p,0.001). However, they only
displayed a 1.8-fold increase in glucose oxidation at 25 mM
glucose. This resulted in 50% lower absolute glucose oxidation in
high versus LP MIN6 cells (Figure 4C). Figure 4D shows the fold
changes in glucose oxidation at 1 and 25 mM glucose.
Lipid oxidation provides an important source of energy to b-
cells. It was measured by 14CO2 produced from the breakdown of
[1-14C]-palmitic acid. In LP cells, lipid oxidation was high at
1 mM glucose and as expected [21], was markedly reduced at
25 mM glucose by ,6-fold (p,0.0001, Figure 4E). In contrast,
basal lipid oxidation in HP MIN6 cells was low (p,0.0001) and
there was no significant change at 25 mM glucose (Figure 4E).
To determine whether the loss of basal lipid oxidation was
important for the phenotype of HP MIN6 cells, bromopalmitate
was used to inhibit lipid oxidation. Higher concentrations of
bromopalmitate caused rapid cell death, indicating the importance
of lipid oxidation (data not shown). There was an indication of
increased insulin secretion with the addition of 0.0625 mM
bromopalmitate for 2 hours (Figure 4G), however, we think this
is still due to toxicity as the raw data without correction for total
insulin content negates the increase (Figure 4H).
Lactate
To determine if the alterations in glucose metabolism in HP
MIN6 cells also involved in increased shunting of glucose into
lactate synthesis rather than oxidative metabolism, we measured
expression of Ldh-A and lactate. No significant differences in
lactate were observed between 1 and 25 mM glucose in LP MIN6
cells (Figure 4F). HP cells had a non-significant decrease at 1 mM
glucose and a significant increase at 25 mM glucose (Figure 4F).
This was still lower than the LP cells. HP MIN6 cells had a 2-fold
increase in Ldh-A expression (p,0.00001, Figure 5A).
Gene Expression between Low and High Passage MIN6
Cells
The mRNA expression of the pancreatic transcription factor
pancreatic duodenal homeobox gene-1 (Pdx1) and proinsulin were
examined. HP MIN6 cells had ,50% increase in Pdx1 expression
(p,0.00001) and ,60% decrease in proinsulin expression
(p,0.00001, Figure 5A). HP MIN6 cells had reduced expression
of mRNAs encoding the glucose transporter Glut1, Hnf4a, and
phosphofructokinase (Pfk, p,0.05, Figure 5B). HP MIN6 cells had
increased expressions of hexokinase (Hk) 1 and 2, with Hk1 increased
approximately 60-fold (p,0.01, Figure 5C). The key glycolytic
gene glucokinase (Gck, also known as hexokinase IV) was decreased
in HP cells (p,0.01, Figure 5C).
Analysis of lipid handling genes revealed that HP cells had
reduced expression of the important lipid synthesis transcription
factor Srebp1c (p,0.0001, Figure 5D) and decreased cholesterol
synthesizing genes HMG CoA reductase and HMG CoA synthase. HP
cells had lower expression of L-b-hydroxyacyl coA dehydrogenase (Hadh)
and higher acyl-coA dehydrogenase medium chain (Acadm), enoyl coA
hydrotase (Ehhadh), and acetyl-coA acyltransferase 1a (Acaa1a)
(Figure 5E).
The mitochondrial uncoupling gene, Ucp2, was decreased by
35% in HP MIN6 cells (p,0.0001, Figure 5F). Only very low
levels of Ucp1 mRNA were present in both LP and HP cells and
did not differ (data not shown). Nampt has been reported in other
tissues to regulate Sirt3 [22] and Sirt3 has been shown to regulate
lipid oxidation [23]. Expression of both Nampt and Sirt3 was
significantly decreased in HP MIN6 cells (Figure 5F).
Discussion
Subjects with T2D lose first phase insulin secretion early in the
natural history of disease progression [9,24–26]. In this study, we
used MIN6 cells to examine defects in first phase insulin secretion.
With high passage these cells had complete loss of first phase
insulin secretion and an overall impairment in GSIS. Previous
studies in LP and HP MIN6 cells have shown both expression and
protein level changes [12–14]; however this is the first report to
profile metabolic changes in these cells. HIT-T15 cells, another
clonal beta-cell type, are also known to lose both first and second
phase GSIS with increased passage. This was attributed to
decreased insulin gene expression and insulin content and was
suggested to be related to constant exposure to 11 mM glucose
[27]. Our HP MIN6 cells displayed similar characteristics, with
reduced insulin granule formation and proinsulin mRNA expres-
sion.
HP cells responded normally to KCl, which works by closing the
KATP channels, downstream of glucose metabolism. Normal KCl-
stimulated insulin secretion clearly indicated that the defects in
first phase insulin secretion are not in insulin synthesis or secretion
capability but lie upstream. L-arginine stimulation of insulin
secretion was retained in HP MIN6 cells, but to a lesser extent
than LP cells. L-arginine stimulates insulin by inducing Ca2+
release from mitochondria via the actions of nitrogen oxides in the
presence of glucose [28,29]. These changes again suggest that the
defects lie upstream of the KATP channels.
The lack of an increase in early insulin secretion in HP MIN6
cells was consistent with the failure of increase in intracellular ATP
concentration with glucose stimulation. Increased ATP:ADP ratio
is crucial in beta-cells as this precedes a cascade of steps necessary
for insulin secretion [2–4]. HP MIN6 cells had significantly
decreased intracellular ATP at 5 minutes after glucose stimulation
but the mechanism or the significance of this is unknown. It is
possible that ATP consuming events such as glycolysis could be
increased shortly after glucose stimulation without subsequent
ATP generation but this needs to be verified. However, impaired
high-glucose stimulated ATP was ultimately a result of decreased
Figure 5. Gene expression in HP and LP MIN6 cells. A) HP MIN6 cells had increased expression of Pdx1 and reduced expression of proinsulin. B)
HP MIN6 cells had reduced expressions of the glucose transporter Glut1 and the key glycolytic gene Pfk. There was a greater than 2-fold increase in
the glycolytic gene Ldh-A in high passage MIN6 cells. C) HP MIN6 cells had increased expressions of Hk1 and Hk2, accompanied with a decrease in
Gck. D) HP MIN6 cells also had reduced expressions of cholesterol synthesizing genes HMG CoA reductase and HMG CoA synthase, and the
transcription factor for lipid synthesis Srebp1C. E) HP MIN6 cells had increased expression of lipid oxidation genes Acadm, Ehhadh, Acaa1a and
increased Hadh expression. F) HP MIN6 cells had reduced Ucp2, Sirt3, and Nampt expression. Error bars are 6 SEM and n=3.
doi:10.1371/journal.pone.0040868.g005
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glucose uptake and impaired glucose oxidation. This was
associated with a significant decrease in Glut1 and a trend to
decreased Glut2. Glut2 is the main glucose sensor in the rodent
beta-cell due to its high Km [30]. There was also a reduction in the
rate limiting glycolytic enzymes Gck and Pfk, both of which are
important in the provision of substrates to the TCA cycle and
oxidative phosphorylation.
Mitochondrial oxidative phosphorylation plays an important
role for insulin secretion, as it provides much of the needed ATP to
change the ATP:ADP ratio [31–33]. The question of the relative
contribution of mitochondrial oxidative phosphorylation versus
other pathways in physiological insulin secretion remains contro-
versial [34–37]. Regardless, in order for oxidative phosphorylation
to be able to generate ATP, substrates must be provided to it by
the glycolytic pathway and the TCA cycle. This flow of substrates
could be inhibited by high Ldh-A expression. Ldh-A converts
pyruvate to lactate and NAD+ and thus decreases pyruvate. Over-
expression of Ldh-A in MIN6 cells has been shown to attenuate
GSIS [38]. However, lactate in HP MIN6 cells was actually
decreased, suggesting that this was not a mechanistic change.
There was no change in oxygen respiration rates as measured by a
Clark-type oxygen electrode (data not shown).
Some lipid synthesis genes were also down-regulated in HP
MIN6 cells, including the important transcription factor Srebp1c.
Lipids, as well as glucose, are a major source of ATP. Per Mole of
substrate, lipid yields more ATP than glucose with up to 136
molecules of ATP generated per palmitate molecule versus 30–36
ATP per glucose molecule. Rough calculations estimating the
amount of ATP able to be produced from glucose and lipid
oxidation indicate that HP MIN6 cells produce more intracellular
ATP compared to LP MIN6 cells at 1 mM glucose. This suggests
that HP MIN6 cells are either utilizing much more ATP at 1mM
glucose or they are wasting energy. HP MIN6 cells, morpholog-
ically different to LP MIN6 cells, were not utilizing extra energy in
increased cell proliferation as they had a slower rate of cell
division, as evidenced by FACS analysis of the BrdU uptake.
The uncoupling proteins function by dissipating the energy
from glucose/lipid oxidation as heat rather than flowing through
the electron transport chain to produce ATP [39]. The uncoupling
protein Ucp1 is the classic and most well known UCP out of five
(Ucp1– Ucp5) but is predominantly expressed in brown adipose
tissue [40,41]. There were very low levels of Ucp1 expression in
both low and HP MIN6 cells and these were not significantly
different. We measured Ucp2 expression as this has been proposed
to be major factor in obesity, beta cell dysfunction, and type 2
diabetes, negatively regulating insulin secretion [42]. Recent
findings have proposed that Ucp2 does not act as an uncoupler
and does not contribute to adaptive thermogenesis [41,43–45]. In
fact, a previous study has shown that a decrease in intracellular
ATP content down-regulated Ucp2 expression in mouse hepato-
cytes [46] and mice with homozygous knockout of Ucp2 have
impaired beta cell function, possibly due to increased oxidative
stress [47]. Interestingly, HP MIN6 cells had a 35% lower
expression in Ucp2. The decreased Ucp2 in HP MIN6 may be
secondary to the markedly decreased ATP content.
Recent findings have indicated the enzyme nicotinamide
phospho-ribosyl-transferase (Nampt) and nicotinamide adenine
dinucleotide (NAD) biosynthesis in insulin secretion and metab-
olism [48,49]. The enzyme Nampt is the rate limiting step in NAD
biosynthesis and mice with a heterozygous deletion of Nampt have
been shown to have impaired glucose tolerance and isolated islets
have reduced GSIS [49]. There is also reduced expression of Sirt3
in streptozotocin induced diabetic mice [50]. The sirtuins are a
family of deactetylases and mono-ADP-ribosyltransferases, of
which there are seven in mammals, that use NAD as a substrate
[51]. It has been previously reported that Sirt1 regulates insulin
secretion by repressing Ucp2 in b-cells [52] but there are no reports
regarding Sirt3 and beta cell function. HP MIN6 cells had
significantly reduced expression of both Nampt and Sirt3.
Sirt3 regulates mitochondrial fatty acid oxidation in other
tissues and Sirt32/2 mice have reduced ATP levels in various
tissues [23,53]. HP MIN6 cells had significantly reduced Sirt3
expression and reduced lipid oxidation, suggesting that decreased
Sirt3 may be driving this.
As lipid oxidation at 1mM glucose failed to provide the cell with
ATP, we believe that HP MIN6 cells attempted to compensate for
this by increasing glucose uptake and oxidation in the basal state.
To determine the importance of basal lipid oxidation, it was
blocked with the non-metabolizable lipid bromopalmitate, but this
caused cell death and further reductions in insulin secretion.
This data shows that HP MIN6 cells have a very different
metabolic profile compared to LP cells. A higher proportion of the
HP MIN6 cells had aneuploidy (data not shown) which in other
cell lines is correlated with genetic instability [54,55]. Clearly,
some of these metabolic changes are causative and some are
compensatory in response to a failure in increasing intracellular
ATP. It is interesting to note that many of these changes also occur
in patients with T2D - impaired insulin response to L-arginine
[56], decreased islet glucose oxidation [57], increased whole body
glucose uptake at basal glucose levels [58], decreased Gck, Hnf4a,
and Pfk, and increased Pdx1 expression [19,57].
We hypothesize that reduced Sirt3 and Nampt expression are a
potential mechanism underlying these metabolic changes, con-
tributing to the decreased lipid oxidation and decreased Glut1 and
some glycolytic gene expression. This led to impaired glucose
uptake and a decrease in glucose oxidation (Figure 6).
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Figure 6. Model of insulin secretion in LP and HP MIN6 cells. HP MIN6 cells increased glucose uptake at 1 mM glucose and decreased
expression of some glycolytic genes. Glucose oxidation is decreased compared to LP MIN6 cells when stimulated with glucose, leading to reduced
intracellular ATP content and impaired insulin secretion. Lipid oxidation was also reduced. Reduced Sirt3 and Nampt gene expression may be
responsible for the impaired metabolism of glucose, ultimately leading to reduced insulin secretion.
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